July launch for Eurand/GSK's novel lamotrigine tablet
This article was originally published in Scrip
Two of Eurand's technologies, its AdvaTab orally-disintegrating tablet and Microcaps, its taste-masking process, are used in GlaxoSmithKline's new oral formulation of lamotrigine, Lamictal ODT, which was approved for marketing earlier this month in the US.
You may also be interested in...
Switzerland’s Polyphor has redefined its business strategy and is aiming to become a leaner organization, with a potential first-in-class immuno-oncologic, balixafortide, in late-stage clinical development for breast cancer.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.